Neuberger Berman Group’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-1,387,017
| Closed | -$27M | – | 1798 |
|
|
2018
Q1 | $27M | Sell |
1,387,017
-69,359
| -5% | -$1.36M | 0.03% | 561 |
|
|
2017
Q4 | $24.3M | Buy |
1,456,376
+571,138
| +65% | +$10.5M | 0.03% | 585 |
|
|
2017
Q3 | $18M | Buy |
885,238
+48,302
| +6% | +$923K | 0.02% | 637 |
|
|
2017
Q2 | $13.5M | Sell |
836,936
-42,149
| -5% | -$623K | 0.02% | 694 |
|
|
2017
Q1 | $11.1M | Buy |
+879,085
| New | +$10.6M | 0.01% | 733 |
|
|
2016
Q3 | – | Sell |
-76,988
| Closed | -$2.22M | – | 1656 |
|
|
2016
Q2 | $2.22M | Buy |
76,988
+14,223
| +23% | +$464K | ﹤0.01% | 963 |
|
|
2016
Q1 | $2.01M | Buy |
62,765
+6,767
| +12% | +$238K | ﹤0.01% | 980 |
|
|
2015
Q4 | $2.39M | Buy |
55,998
+366
| +0.7% | +$14.6K | ﹤0.01% | 980 |
|
|
2015
Q3 | $1.96M | Buy |
+55,632
| New | +$2.51M | ﹤0.01% | 1024 |
|
|
2015
Q2 | – | Sell |
-819,619
| Closed | -$38.4M | – | 1654 |
|
|
2015
Q1 | $38.4M | Buy |
+819,619
| New | +$32.6M | 0.04% | 491 |
|
|
2014
Q1 | – | Sell |
-417,550
| Closed | -$10.5M | – | 1693 |
|
|
2013
Q4 | $10.5M | Buy |
417,550
+4,900
| +1% | +$109K | 0.01% | 788 |
|
|
2013
Q3 | $8.45M | Buy |
+412,650
| New | +$8.52M | 0.01% | 816 |
|
Neuberger Berman Group's IPXL Position: Q2 2018 in Review
Neuberger Berman Group sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 1,387,017 shares — an estimated $27M sold.
Neuberger Berman Group first reported a position in IPXL in Q3 2013 and held it in 12 quarters. The position peaked at $38.4M in Q1 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Neuberger Berman Group reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Neuberger Berman Group sold 1,387,017 Impax Laboratories, Inc. shares in Q2 2018, an estimated $27M.
- Neuberger Berman Group first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 12 quarters.
- Neuberger Berman Group's Impax Laboratories, Inc. position peaked at $38.4M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Neuberger Berman Group's 13F filing for Q2 2018, filed 13 Aug 2018.